Company Alterity Therapeutics Limited Nasdaq
Equities
ATHE
US02155X2053
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.14 USD | -2.73% | -5.31% | -14.06% |
04-29 | Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases | CI |
04-16 | ADRs End Lower, Purple Biotech Ltd. Declines 29% | DJ |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 63 | 17-04-30 |
Geoffrey Kempler
FOU | Founder | 69 | 97-11-10 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 14-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Geoffrey Kempler
FOU | Founder | 69 | 97-11-10 |
Peter Marks
BRD | Director/Board Member | 68 | 05-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 45 | 11-08-07 |
Brian Meltzer
BRD | Director/Board Member | 70 | 99-12-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,802,360,380 | 2,436,015,074 ( 86.93 %) | 0 | 86.93 % |
Company contact information
Alterity Therapeutics Ltd.
350 Collins Street Level 14
3000, Melbourne
+61 3 9349 4906
http://www.alteritytherapeutics.comSector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.28% | 48.09B | |
+48.09% | 40.62B | |
-3.99% | 40.43B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.02% | 11.88B | |
-2.75% | 11.8B |
- Stock Market
- Equities
- ATH Stock
- ATHE Stock
- Company Alterity Therapeutics Limited